Introduction: In recent years, climate change and human activity have modified marine biotopes, including the widening distribution of harmful algal blooms (HABs). Bloom events predominated by microalgae of the genus have been described on the French Mediterranean coast, but in 2021 an unprecedented bloom occurred on the French Basque coast. The objective of this study is to describe the health impact of the spp bloom that occurred on the French Basque coast in 2021.
Methods: A historical cohort was conducted, including cases of possible exposure to spp registered at the Centre Antipoison de Nouvelle-Aquitaine between July 1 and September 30, 2021.
Results: Of 674 patients with possible toxicity due to spp, 96.9% had bathed in contaminated waters. Most of them developed respiratory tract symptoms (64.4% of patients). The time to the onset of symptoms was <6 h for 73.6% of 174 short-term (<24 h) exposed patients. The median duration of symptoms was 7.5 days for occupational (e.g., lifeguards and surfing instructors) and 3 days for recreational exposures. There were no severe cases. In total, 3% of the cases were of moderate severity, and 97% were of minor severity, according to the Poisoning Severity Score.
Conclusion: Toxic reactions caused by spp are mostly benign. The clinical picture is similar to that described following exposures to cf. blooms in the Mediterranean area since the end of the 20th century. spp are present on the Basque coast. The ecological factors promoting its blooms remain to be clarified.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/10806032231220405 | DOI Listing |
Antibiotics (Basel)
December 2024
Microbiology Laboratory, Bicêtre University Hospital, AP-HP Paris Saclay University, 94270 Le Kremlin-Bicêtre, France.
Background: Meropenem-vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an effective inhibitor of KPC enzymes in vitro. This study aimed to describe the initial uses and efficacy of MEM-VAB for compassionate treatment during the first 21 months following its early access in France.
Method: A national multicenter retrospective study was conducted, including all patients who received at least one dose of MEM-VAB between 20 July 2020, and 5 April 2022.
J Allergy Clin Immunol Pract
January 2025
Sorbonne Université, service de médecine interne, AP-HP, Hôpital Saint Antoine, F-75012 Paris, France. Electronic address:
Background: Angioedema (AE) due to acquired C1-inhibitor deficiency (AAE-C1-INH) is a rare disease associating recurrent edema of mucosa and skin. Several underlying diseases have been reported, mainly lymphoproliferative diseases and monoclonal gammopathy. However, 15 to 20% of patients never exhibit such a hematological condition.
View Article and Find Full Text PDFEBioMedicine
December 2024
Digestive Diseases and Microbiota Group, Girona Biomedical Research Institute (IDIBGI), 17190, Salt, Girona, Spain. Electronic address:
Eur J Epidemiol
November 2024
ULR 2694-METRICS: Évaluation Des Technologies de Santé Et Des Pratiques Médicales, University of Lille, CHU Lille, 59000, Lille, France.
While pancreatic adenocarcinoma (PA) incidence is increasing, especially in France, the association between pesticides and PA remains unclear. The aims of this study were to assess the spatiotemporal distribution of the incidence of PA in France between 2011 and 2021 and to determine whether pesticide exposure was associated with higher risk of PA. We employed a disease-mapping and ecological regression approach with medicoadministrative data covering 99% of the French population.
View Article and Find Full Text PDFSupport Care Cancer
November 2024
Université de Reims Champagne-Ardenne, BioSpecT, CHU Reims, Service Pharmacie, 51100, Reims, France.
Purpose: The prevalence of type 2 diabetes mellitus (T2DM) in cancer patients is high. During the medication review process, clinical pharmacists could detect and manage drug-related problems (DRP) to optimize pharmacotherapy but there is a need to standardize pharmacists' interventions (PI) especially for T2DM-related DRP. The present study aims to describe DRP in cancer patients with T2DM undergoing anticancer treatment (AT) and to propose related preliminary guidelines to manage T2DM-related DRP.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!